Objectives -To assess the relationship between haematocrit and risk of major ischaemic heart disease events. Design -Prospective study of a cohort of men followed up for 9 5 years. Setting-General practices in 24 towns in England, Wales, and Scotland (British Regional Heart Study). Subjects -Altogether 7735 men aged 40-59 years at screening, who were selected at random from one general practice in each of 24 towns, were studied. Main outcome measures -Fatal and nonfatal ischaemic heart disease events. Results -Risk of major ischaemic heart disease events was significantly increased at haematocrit levels of > 46-0%. Men with raised haematocrit ( >46-0%) showed a 30% increase in relative risk (RR) of major ischaemic heart disease events (RR= 132; 95% confidence intervals (CI) 1P10,1P57, p<0-01) compared with those with values below 46-0%, even after adjustment for age, social class, smoking, body mass index, physical activity, blood cholesterol, lung function (FEVy), and pre-existing evidence of ischaemic heart disease. Further adjustment for systolic blood pressure reduced the risk slightly (RR= 1-27; 95% CI 1-06,1-51, p = 0 02) but it remained significant. The relationship was seen in men with and without pre-existing evidence of ischaemic heart disease. The study suggests that an increased haematocrit level plays a part in the development of major ischaemic heart disease events. most of these studies a linear relationship between haematocrit and outcome has been assumed. A recent study, however, has shown a significantly increased risk of heart attacks in subjects with levels above 46 0% compared with those with values below this, independent of the recognised risk factors.8 This suggests that the relationship may not be linear and that risk may be increased only above certain threshold levels of haematocrit. This study examines the relationship between haematocrit and risk of major IHD events in a large prospective study of middle-aged men, and focuses on the role of cardiovascular risk factors in the relationship between ischaemic heart disease and haematocrit.
Patients with polycythaemia rubra vera who have a noticeably raised haematocrit level experience an increased risk of ischaemic heart disease (IHD) .' This may be a consequence of the influence of haematocrit on blood viscosity.23 Recent evidence also suggests that the plasma component of viscosity may play a role in the development of atherosclerosis.4 However, population studies examining the relationship between haematocrit or haemoglobin and major IHD events have been inconclusive. Most studies have reported a positive association between haematocrit or haemoglobin (which are highly correlated) and the risk of heart attacks,512 and some of these have found the association to be independent of the coronary risk factors."8 Other studies have found the relationship to be dependent on established cardiovascular risk factors, for example smoking, blood pressure, and blood cholesterol,'0 12 and others have reported no association.'31 '4 In most of these studies a linear relationship between haematocrit and outcome has been assumed. A recent study, however, has shown a significantly increased risk of heart attacks in subjects with levels above 46 0% compared with those with values below this, independent of the recognised risk factors. 8 This suggests that the relationship may not be linear and that risk may be increased only above certain threshold levels of haematocrit. This study examines the relationship between haematocrit and risk of major IHD events in a large prospective study of middle-aged men, and focuses on the role of cardiovascular risk factors in the relationship between ischaemic heart disease and haematocrit.
SUBJECTS AND METHODS
The British Regional Heart Study is a large prospective study of cardiovascular disease comprising 7735 men aged 40-59 years selected from the age-sex registers of one group general practice in each of 24 towns in England, Wales, and Scotland. The criteria for selecting the town, the general practice, and the subjects as well as the methods of data collection, have been reported. ' The men attended the examination centre over a 10 hour period between 8.30 am and 6.30 pm on weekdays and were not asked to fast or to abstain from alcohol beforehand. The London School of Hygiene sphygmomanometer was used to measure blood pressure twice in succession, using a standard adult cuff on the right arm of all subjects and with the subjects seated and the arm supported on a cushion. The mean of the two readings was used in the analysis and all blood pressure readings were adjusted for observer variation within each town.'8
PRE-EXISTING IHD
The men were asked whether a doctor had ever told them that they had angina or myocardial infarction (heart attack, coronary thrombosis), stroke, and a number of other disorders. The WHO (Rose) chest pain questionnaire was administered to all men at the initial examination'9 and a three-orthogonal lead electrocardiogram was recorded at rest and analysed by computer in the Department of Medical Cardiology, Glasgow Royal Infirmary. Men with evidence of IHD were defined as those with a recall of doctor diagnosis of angina or heart attack, WHO (Rose) questionnaire responses indicating angina (definite or possible) or possible myocardial infarction, or electrocardiographic evidence of definite or possible myocardial ischaemia or myocardial infarction. Definite myocardial infarction is defined as men with recall of a doctor diagnosis of a myocardial infarction or evidence of definite myocardial infarction on electrocardiogram.
FOLLOW UP All men have been followed up for all cause mortality and for cardiovascular morbidity for 9.5 years.20 Information on death was collected through the established "tagging" procedures provided by the National Health Service registers in Southport (England and Wales) and Edinburgh (Scotland). Fatal IHD events included all deaths with ischaemic heart disease as the underlying cause (International Classification of Disease, 9th revision, codes 410-414) which occurred during the period of follow up, irrespective of non-fatal events which may have preceded the fatal event during the follow up period. A non-fatal heart attack was one which satisfied at least two of the following WHO criteria: (a) preceded by severe prolonged chest pain, (b) electrocardiographic evidence of myocardial infarction, (c) cardiac enzyme changes associated with myocardial infarction.
STATISTICAL METHODS
Multiple logistic regression was used to obtain the relative risks for the five haematocrit groups adjusted for age, smoking, social class, physical activity, body mass index, lung function, pre-existing IHD, blood cholesterol, and systolic blood pressure. Age, body mass index, lung function, blood cholesterol, and systolic blood pressure were fitted as continuous variables, smoking as four dummy variables (never, ex-smokers, light, moderate, and heavy), and social class as two dummy variables (manual, non-manual, and Armed Forces). Haematocrit was fitted as four dummy variables for the five haematocrit groups and in some of the analyses as one dummy variable (> 46% v the rest). Fitting haematocrit as five categorical groups makes no assumptions of a linear relationship between haematocrit and risk of major IHD events.
Results
Data on haematocrit were available on 7346 men with a mean (SD) of 44 47% (3-16%), range 25-63%. During the follow up period of 9 5 years in these 7346 men there were 580 major IHD events (non-fatal heart attacks and all IHD deaths including sudden cardiac death). Figure 1 shows the crude heart attack rate/ 1000/year by the five haematocrit groups in all men. There was little difference in risk of major IHD events in men with haematocrit levels below 46 0%. Risk was significantly increased at levels of 46-0% and above. A global test for overall difference between the five groups was significant (p<0 001).
HAEMATOCRIT AND RISK OF MAJOR IHD EVENTS
HAEMATOCRIT AND CORONARY RISK FACTORS Table 1 shows the relationship between the five haematocrit groups and factors associated 6- HAEMATOCRIT, BLOOD LIPIDS, AND BLOOD PRESSURE 4 Figure 2 Raised haematocrit ( >46%) and adjusted relative risk of major ischaemic heart disease (IHD) events in relation to smoking, systolic blood pressure, and blood cholesterol. Adjusted for age, social class, smoking, physical activity, body mass index, lung function, pre-existing IHD, diabetes and each of the other factors.
atocrit and the risk of IHD events. Haematocrit is significantly associated with total serum protein concentration (r =0 18) and with its main components, albumin (r =0 13) and globulin (r = 0 19). However, the total serum protein concentration showed no association with the risk of IHD events once age, smoking, blood pressure, blood cholesterol, and social class are taken into account. The relationship between haematocrit and risk of IHD is thus unaffected by adjustment for total serum protein concentration.
Discussion
In this study of middle-aged British men, a raised haematocrit (, 46) was associated with an increase in risk of major IHD events independent of age, social class, body weight, physical activity, lung function, and pre-existing evidence of IHD. Although most studies have found a positive association between haematocrit and risk of heart attacks,5-'2 many have found the relationship to be dependent on established coronary risk factors,'0 12 in particular blood pressure and blood cholesterol. In this study haematocrit showed a strong positive association with both blood cholesterol and blood pressure. The positive association between haematocrit and blood pressure is well documented2223 and it is thought that a raised haematocrit predisposes to hypertension. If raised haematocrit does indeed produce a rise in blood pressure, then adjusting for blood pressure may not be appropriate, except to assess whether the relationship is mediated through blood pressure. Several studies have also noted a strong positive association between blood cholesterol and haematocrit and it is suggested that the association may be due to changes in plasma volume resulting in both a rise in blood cholesterol and in haematocrit levels.2>25 It has also been reported that cholesterol and triglycerides cause rigidification of erythrocytes because of metabolic relations between lipoprotein fractions and cell membrane, and this is likely to result in increased haematocrit.29 In the present study the positive relationship between haematocrit and major IHD events was reduced after adjusting for blood cholesterol in addition, but the relationship remained significant. Further adjustment for systolic blood pressure reduced the excess risk further but the risk still increased at levels of 46 0% or above. It is well established that the presence of IHD is associated with increased haematocrit levels.22-24 However, the positive relationship between haematocrit and the risk of heart attacks was seen in the present study even after exclusion of men with evidence of IHD. Indeed the relationship was similar in both men with and without IHD in that haematocrit levels >o46 0% were associated with about a 30% increase in risk in both groups.
It is of some interest that the most noticeable effects of adjustments for blood cholesterol and for systolic blood pressure were seen at the highest levels of haematocrit (> 48 0%). Although some of the excess risk was due to raised systolic blood pressure, this did not account for all the excess risk seen. This implies that the mechanism in the haematocrit-IHD relationship is either to some extent independent of blood lipids and blood pressure or that the process of adjustment does not take into It is also suggested that fibrinogen variations within the levels encountered in the general population may reflect the activity and instability of the atherosclerotic plaque.33 However, a recent report from the Caerphilly study suggests that plasma viscosity has an influence on IHD risk which is independent from that of fibrinogen, although the conclusion is dependent on the precise adjustment used.4 Fibrinogen was not measured in this study and thus the independent contributions of haematocrit, plasma viscosity, and fibrinogen concentration to the IHD risk need to be examined further in longitudinal studies with data on all these factors.
CONCLUSION
This study suggests that a raised haematocrit plays a role in the development of major IHD.
There was no difference in the risk of IHD at haematocrit levels within the range 42-0-45-9 observed in population studies. At levels of 46-0% and beyond the risk of heart attacks increased. Some of the increased risk of IHD was associated with the established coronary risk factors but even after adjusting for these risk factors there still remained an independent effect of a raised haematocrit on the risk of major IHD events. This effect could be related to the imprecision with which the adjusted variables are measured, or it could be truly independent. The findings support the suggestion that blood rheology, of which the haematocrit is an important component, plays a part in the development of IHD.
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